Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Validation of a model to estimate survival in ambulatory patients with hepatocellular carcinoma: a single‐centre cohort study
Nam, Byung‐Ho, Kwak, Hee Won, Kim, W. Ray , Kim, Bo Hyun , Park, Joong‐Won

Liver International | March 7, 2014 | Volume: 34 | Issue: 7 | Pages: No page available

10.1111/liv.12519 | PMID 24606128 Get It

AbstractBackground & AimsSurvival of patients with hepatocellular carcinoma (HCC) is determined by hepatic function and tumour extent. Recently, a new Model to Estimate Survival in Ambulatory HCC patients (MESIAH) was proposed to predict overall survival in ambulatory HCC patients. This study aimed to evaluate the prognostic performance of the MESIAH score in an independent cohort of HCC patients.MethodsA cohort of 1969 patients newly diagnosed with HCC at the National Cancer Center, Korea between January 2004 and December 2009 was used for validation of the MESIAH score. The model's performance was assessed using C‐statistics, the likelihood ratio (LR) χ2 value and Akaike information criterion (AIC).ResultsPatients in the cohort had a median age of 56 years and 83.2% were men. Hepatitis B virus infection was present in 74.6 and 81.6% had a Child–Pugh class A. The median overall survival was 21.4 months. The MESIAH score had a higher degree of discrimination, with a C‐statistic of 0.792 [95% confidence interval (CI), 0.782–0.803], when compared with the Barcelona Clinic Liver Cancer (BCLC) staging system [0.665 (95% CI, 0.653–0.678), P < 0.001]. The LR χ2 value and the AIC of MESIAH were also better than those of BCLC, Cancer of the Liver Italian Program, Japan Integrated Scoring and Tokyo score. The observed survival in the cohort closely matched that predicted by the MESIAH score.ConclusionsThe new prognostication model MESIAH accurately estimated the overall survival of Korean HCC patients and may be useful in future research as well as individual patient care.
Voiding Chain Cystourethography: Assessing A Historical Test's Role in Selection for Urethrolysis
Petrou, Steven P. , Ryan, Karen, Metz-Kudashick, Dorothea, Thiel, David D. , Heckman, Michael G.

International braz j urol | March 7, 2014 | Volume: 39 | Issue: 4 | Pages: 498-505

10.1590/s1677-5538.ibju.2013.04.07 | PMID 24054397 Get It

Beyond the Learning Curve: Transapical Versus Transfemoral Transcatheter Aortic Valve Replacement in the Treatment of Severe Aortic Valve Stenosis
Greason, Kevin L. , Suri, Rakesh M. , Rihal, Charanjit S. , Holmes, David R. , Mathew, Verghese, Nkomo, Vuyisile T. , Rihal, Charanjit S.

Journal of Cardiac Surgery | March 7, 2014 | Volume: 29 | Issue: 3 | Pages: 303-307

10.1111/jocs.12323 | PMID 24601949 Get It

Comparison of baroreflex sensitivity with a fall and rise in blood pressure induced by the Valsalva manoeuvre
Wada, Naoki , Gehrking, Tonette L., Sletten, David M., Schmelzer, James D., Low, Phillip A. , Singer, Wolfgang

Clinical Science | March 7, 2014 | Volume: 127 | Issue: 5 | Pages: 307-313

10.1042/cs20130802 | PMID 24597842 Get It

The baroreflex plays a key role in human BP (blood pressure) regulation. Its efferent limb consists of a vagal and a sympathetic component. The Valsalva manoeuvre is widely used to quantify vagal baroreflex function [BRS_vagal (vagal baroreflex sensitivity)], but most studies have focused on the R–R interval response to BP decrement, even though the subsequent response to an increment in BP is important and different. In the present study, we sought to evaluate whether BRS_vagal can be determined from BRSvagalinc (BRS_vagal derived from the rise in BP during phases III–IV of the Valsalva manoeuvre), to assess the association between BRSvagalinc and BRSvagaldec (BRS_vagal derived from the preceeding BP decrement) and to validate BRSvagalinc as an index of autonomic function. We studied patients with severe autonomic failure (n=49, 25 female), mild autonomic failure (n=25, 11 female) and matched normal controls (n=29, 15 female). BRSvagalinc and BRSvagaldec were calculated as the regression slope of R–R interval and systolic BP during phases III–IV and the early phase II of the Valsalva manoeuvre respectively, and compared these with other autonomic indices across the groups. BRSvagalinc was calculated in all subjects and correlated highly with BRSvagaldec (r=0.72, P&lt;0.001). BRSvagalinc also correlated significantly with BP changes during phases II and IV of the Valsalva manoeuvre and sympathetic barosensitivity. BRSvagalinc was significantly different between the groups, being highest in the controls and lowest in patients with severe autonomic failure. In conclusion, vagal BRS, determined by relating R–R interval with the BP increase following phase III, is a valuable autonomic index, provides additional information about vagal baroreflex function and reflects overall severity of autonomic failure.
Regional Differences in Breast Cancer Biomarkers in American Indian and Alaska Native Women
Kaur, Judith S. , Vierkant, Robert A. , Hobday, Timothy J. , Visscher, Daniel W., Vierkant, Robert A

Cancer Epidemiology, Biomarkers & Prevention | March 7, 2014 | Volume: 23 | Issue: 3 | Pages: 409-415

10.1158/1055-9965.epi-13-0738 | PMID 24609850 Get It

Abstract Background: Breast cancer is not a homogeneous disease, but several different and unique subtypes defined by gene expression analysis. Incidence and mortality rates vary by almost 3-fold between Alaska (highest) and the Southwestern tribes (lowest). We hypothesized that these differences may be due to, in part, varying levels of biologic tumor aggressiveness. Methods: A biorepository of the North Central Cancer Treatment Group with 95 cases of American Indian and Alaska Native (AIAN) women with adenocarcinoma of the breast surgically treated from 1990 to 2000 was tested for several biomarkers. Comparison distributions of biomarker values across state of residence using t tests for continuous (p53, MIB-1, cyclin D) and ordinally scaled markers [EGF receptor (EGFR), BCL-2, Her2] and χ2 tests of significance for binary markers [estrogen receptor (ER), progesterone receptor (PR)] were done. Results: Significant regional differences in some biomarker expression levels were seen. No increase was observed in “triple-negative” breast cancer or Her2 overexpression in these cases. Conclusions: Despite a 3-fold difference in breast cancer mortality in Alaska Native versus Southwestern American Indians, standard biomarkers such as ER, PR, and Her2 neu expression did not explain the disparity. Impact: There is a need for research to understand the biologic basis of breast cancer disparities in AIAN women. Potential for a prospective trial will be explored with tribes. See all articles in this CEBP Focus section, “Community Network Program Centers.” Cancer Epidemiol Biomarkers Prev; 23(3); 409–15. ©2014 AACR.
Impact of Prescription Patterns on Compliance With Follow-Up Visits at an Urban Teaching Primary Care Continuity Clinic
Sorita, Atsushi , Funakoshi, Tomohiro, Kashan, Glenn, Young, Edwin, Park, Jayson

Journal of Primary Care & Community Health | March 7, 2014 | Volume: 5 | Issue: 3 | Pages: 188-193

10.1177/2150131914523294 | PMID 24603776 Get It

Background: Although limiting prescription refills is considered as a strategy to increase compliance with the treatment regimen and follow-up, no literature exists to support its effectiveness. We sought to investigate whether decreasing the number of prescription refills affects no-show rate at an urban teaching primary care continuity clinic in New York. Methods: Eight teaching attending physicians and 19 residents implemented a “new prescribing strategy” from February 9 to 22, 2012, which limited the number of refills only to cover until the next intended clinic visit. All adult patient visits were included if follow-up visits were requested to be scheduled within 3 months and prescriptions were given through an electronic prescription system. No-show rates for the first follow-up visits up to 120 days from the initial visits during the interventional period were compared with those during the baseline period (December 15-28, 2011). Results: Two hundred twenty-one patients in the baseline period and 278 in the interventional period were included in the analysis. Median total supply of prescription was 6 and 3 months, respectively ( P < .001). The no-show rates were not significantly different between the 2 periods (19.0% [42/221] vs 16.6% [46/278], P = .5). In multivariate regression analysis, the no-show rate did not change significantly during the interventional period compared with the baseline period (odds ratio [OR] 1.0; 95% confidence interval, 0.6-1.5; P = .8). Younger age (OR 1.03 per year, P = .008), male gender (OR 2.0, P = .003), Medicaid or Medicare insurance (OR 3.7, P = .01; OR 4.2, P = .02), and diagnosis of diabetes (OR 1.8, P = .04) or asthma (OR 2.0, P = .03) were associated with higher no-show rates. Conclusions: Reducing the number of refills did not significantly affect no-show rates in the immediate follow-up. Alternative strategies should be considered to minimize no-shows.
Health assessment of commercial drivers: a meta-narrative systematic review
Dabrh, Abd Moain Abu , Firwana, Belal , Cowl, Clayton T. , Steinkraus, Lawrence W., Murad, M. Hassan , Abu Dabrh, Abd Moain, Prokop, Larry J. , Murad, M Hassan , Abu Dabrh, Abd Moain

BMJ Open | March 6, 2014 | Volume: 4 | Issue: 3 | Pages: e003434

10.1136/bmjopen-2013-003434 | PMID 24604478 Get It

Background Motor vehicle accidents associated with commercial driving are an important cause of occupational death and impact public safety. Objectives We summarise the evidence regarding the type, prevalence and impact of medical conditions discovered during health assessment of commercial drivers. Evidence review We conducted a systematic review of multiple electronic databases and made a manual search for relevant studies that enrolled commercial drivers in any country and reported the outcomes of health assessment carried out in the context of commercial driving through November 2012. Data were extracted by a pair of independent reviewers and synthesised using a metanarrative approach. Results We identified 32 studies of moderate methodological quality enrolling 151 644 commercial drivers (98% men). The prevalence of multiple health conditions was high (sleep disorders 19%, diabetes 33%, hypertension 23% and obesity 45%). Some conditions, such as sleep disorders and obesity, were linked to increased risk of crashes. Evidence on several other highly relevant medical conditions was lacking. Cost-effectiveness data were sparse. Conclusions Several medical conditions are highly prevalent in commercial drivers and can be associated with increased risk of crashes, thus providing a rationale for health assessment of commercial drivers.
Esophageal cancer screening in achalasia: is there a consensus?
Geno, Debra M., Katzka, David A. , Ravi, Karthik

Diseases of the Esophagus | March 6, 2014 | Volume: 28 | Issue: 3 | Pages: 299-304

10.1111/dote.12196 | PMID 24602003 Get It

Accelerations of the Waist and Lower Extremities Over a Range of Gait Velocities to Aid in Activity Monitor Selection for Field-Based Studies
Morrow, Melissa M. , Hurd, Wendy J., Fortune, Emma , Lugade, Vipul , Kaufman, Kenton R. , Morrow, Melissa M B, Morrow, Melissa M , Kaufman, Kenton R

Journal of Applied Biomechanics | March 6, 2014 | Volume: 30 | Issue: 4 | Pages: 581-585

10.1123/jab.2013-0264 | PMID 24610379 Get It

This study aimed to define accelerations measured at the waist and lower extremities over a range of gait velocities to provide reference data for choosing the appropriate accelerometer for field-based human activity monitoring studies. Accelerations were measured with a custom activity monitor (± 16g) at the waist, thighs, and ankles in 11 participants over a range of gait velocities from slow walking to running speeds. The cumulative frequencies and peak accelerations were determined. Cumulative acceleration amplitudes for the waist, thighs, and ankles during gait velocities up to 4.8 m/s were within the standard commercial g-range (± 6g) in 99.8%, 99.0%, and 96.5% of the data, respectively. Conversely, peak acceleration amplitudes exceeding the limits of many commercially available activity monitors were observed at the waist, thighs, and ankles, with the highest peaks at the ankles, as expected. At the thighs, and more so at the ankles, nearly 50% of the peak accelerations would not be detected when the gait velocity exceeds a walking velocity. Activity monitor choice is application specific, and investigators should be aware that when measuring high-intensity gait velocity activities with commercial units that impose a ceiling at ± 6g, peak accelerations may not be measured.
Gastrointestinal morbidity in obesity
Camilleri, Michael , Acosta, Andrés

Annals of the New York Academy of Sciences | March 6, 2014 | Volume: 1311 | Issue: 1 | Pages: 42-56

10.1111/nyas.12385 | PMID 24602085 Get It

Obesity is a complex disease that results from increased energy intake and decreased energy expenditure. The gastrointestinal system plays a key role in the pathogenesis of obesity and facilitates caloric imbalance. Changes in gastrointestinal hormones and the inhibition of mechanisms that curtail caloric intake result in weight gain. It is not clear if the gastrointestinal role in obesity is a cause or an effect of this disease. Obesity is often associated with type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). Obesity is also associated with gastrointestinal disorders, which are more frequent and present earlier than T2DM and CVD. Diseases such as gastroesophageal reflux disease (GERD), cholelithiasis, or nonalcoholic steatohepatitis are directly related to body weight and abdominal adiposity. Our objective is to assess the role of each gastrointestinal organ in obesity and the gastrointestinal morbidity resulting in those organs from the effects of obesity.